Coronavirus Spike Nanoparticle Formulation for Cold-Chain Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing vaccines against highly sophisticated pathogens like SARS-CoV-2 is challenging due to their evasion mechanisms and the need for stability in various environments without refrigeration, while inducing antibodies that block or neutralize infectious agents.
Innovation Solution
Non-naturally occurring CoV S polypeptides, particularly BV2373, are engineered with inactive furin cleavage sites and other modifications to enhance stability and epitope presentation, formulated into nanoparticles with adjuvants like MATRIX-M™ to stimulate robust immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccine formulations are used, then the vaccine can induce immune responses, but the stability in various environments without refrigeration deteriorates
Solution Approach 1:
The patent modifies the physical and chemical parameters of the vaccine formulation by incorporating specific excipients and adjuvants that enhance thermal stability. The modified CoV S polypeptides are formulated with stabilizing agents that maintain structural integrity across a broader temperature range, reducing the need for strict refrigeration while preserving immunogenicity.
Solution Approach 2:
The vaccine employs a composite formulation combining modified CoV S polypeptides withMatrix-M™ adjuvant and other excipients. This composite structure provides both the immunogenic antigen and stabilizing components that work synergistically to maintain vaccine stability under varying environmental conditions, including temperatures without refrigeration.
2Reliability
If the vaccine induces strong immune responses, then neutralizing antibodies are produced, but the pathogen's evasion mechanisms counteract this effectiveness
Solution Approach 1:
The vaccine focuses on presenting specific critical epitopes of the CoV S polypeptide that are essential for neutralizing antibody generation but less susceptible to pathogen mutation and evasion. By segmenting the antigen presentation to highlight conserved regions, the vaccine induces immune responses targeted at immutable viral structures.
Solution Approach 2:
The modified CoV S polypeptides incorporate specific mutations (K986P, V987P) at localized positions to stabilize the prefusion conformation and enhance presentation of immunodominant epitopes. This local modification strategy optimizes the antigen's ability to induce neutralizing antibodies while maintaining structural features that are difficult for the pathogen to evade.
3Reliability
If modified CoV S polypeptides are engineered for enhanced stability, then epitope presentation is improved, but the complexity of vaccine formulation increases
Solution Approach 1:
The patent extracts and isolates the critical stabilizing mutations (K986P, V987P) and essential epitopic regions from the full CoV S protein sequence. By focusing only on the necessary modified polypeptide segments rather than the complete protein, the formulation achieves enhanced stability and epitope presentation while managing complexity through targeted inclusion of only essential components.
Data Source
AI summary
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.